ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last841 to 860 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Open Group vs Masked Group: Number of Neonates With Shoulder Dystocia During Delivery141 of 5,532

158 of 5,576

-0.3 points

-0.9 to 0.3

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Neonatal Deaths (Primary Outcome Component)3 of 5,532

1 of 5,576

0.0 points

-0.1 to 0.1

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Participants Who Had a Postpartum Blood Transfusion80 of 5,532

74 of 5,576

0.1 points

-0.3 to 0.6

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Infants With Meconium Aspiration Syndrome20 of 5,532

20 of 5,576

0.0 points

-0.2 to 0.2

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Participants With Primary Composite Outcome52 of 5,532

40 of 5,576

0.2 points

-0.1 to 0.6

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Participants With Chorioamnionitis286 of 5,532

269 of 5,576

0.3 points

-0.5 to 1.2

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Neonates Intubated for Ventilation at Delivery (Primary Outcome Component)42 of 5,532

27 of 5,576

0.3 points

-0.0 to 0.6

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Infants With a Major Congenital Malformation38 of 5,532

23 of 5,576

0.3 points

-0.0 to 0.6

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Participants Experiencing Postpartum Endometritis71 of 5,532

88 of 5,576

-0.3 points

-0.7 to 0.1

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Infants Who Experienced Neonatal Seizure (Primary Outcome Component)3 of 5,532

4 of 5,576

-0.0 points

-0.1 to 0.1

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: Number of Infants Admitted to Special Care Nursery498 of 5,532

470 of 5,576

0.6 points

-0.5 to 1.6

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Open Group vs Masked Group: serious adverse events35 of 5,532

21 of 5,576

0.3 points

-0.0 to 0.5

11,108NCT01131260

Fetal ST Segment and T Wave Analysis in Labor

Cangrelor Treatment Arm vs Clopidogrel Treatment Arm: serious adverse events122 of 5,529

105 of 5,527

0.3 points

-0.2 to 0.8

11,056NCT01156571

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

TICAGRELOR vs PLACEBO: ICH or Fatal Bleeding Event22 of 5,523

6 of 5,493

0.3 points

0.1 to 0.5

11,016NCT03354429

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

TICAGRELOR vs PLACEBO: Premature Permanent Discontinuation of IP Due to Bleeding152 of 5,523

32 of 5,493

2.2 points

1.7 to 2.7

11,016NCT03354429

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

TICAGRELOR vs PLACEBO: Bleeding Event That Fulfils Serious Adverse Event Criteria and is Categorised as GUSTO Severe28 of 5,523

7 of 5,493

0.4 points

0.2 to 0.6

11,016NCT03354429

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

TICAGRELOR vs PLACEBO: Bleeding Event That Fulfils Serious Adverse Event Criteria and is Categorised as GUSTO Moderate/Severe36 of 5,523

11 of 5,493

0.5 points

0.2 to 0.7

11,016NCT03354429

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

TICAGRELOR vs PLACEBO: Ischaemic Stroke276 of 5,523

345 of 5,493

-1.3 points

-2.1 to -0.4

11,016NCT03354429

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

TICAGRELOR vs PLACEBO: Composite of Subsequent Stroke or Death303 of 5,523

362 of 5,493

-1.1 points

-2.0 to -0.2

11,016NCT03354429

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

Ticagrelor vs Placebo: deaths from any cause40 of 5,523

32 of 5,493

0.1 points

-0.2 to 0.5

11,016NCT03354429

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=43

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01131260-0ce0d8c7",
        "title": "Open Group vs Masked Group: Number of Neonates With Shoulder Dystocia During Delivery",
        "summary": "141 of 5532 against 158 of 5576; risk difference -0.3 points, 95% interval -0.9 to 0.3; NCT01131260, Fetal ST Segment and T Wave Analysis in Labor",
        "record": "/library/comparisons/NCT01131260-0ce0d8c7",
        "nct_id": "NCT01131260",
        "kind": "outcome",
        "participants": 11108,
        "risk_difference": {
          "value": -0.002847655119399224,
          "lower": -0.00890665441256894,
          "upper": 0.0031960270334231234
        },
        "group_1": "141 of 5,532",
        "group_2": "158 of 5,576",
        "difference": "-0.3 points",
        "interval": "-0.9 to 0.3",
        "trial_title": "Fetal ST Segment and T Wave Analysis in Labor"
      },
      {
        "id": "NCT01131260-1f9a450c",
        "title": "Open Group vs Masked Group: Number of Neonatal Deaths (Primary Outcome Component)",
        "summary": "3 of 5532 against 1 of 5576; risk difference 0.0 points, 95% interval -0.1 to 0.1; NCT01131260, Fetal ST Segment and T Wave Analysis in Labor",
        "record": "/library/comparisons/NCT01131260-1f9a450c",
        "nct_id": "NCT01131260",
        "kind": "outcome",
        "participants": 11108,
        "risk_difference": {
          "value": 0.0003629593205463763,
          "lower": -0.0005463073646726211,
          "upper": 0.0014243083597192056
        },
        "group_1": "3 of 5,532",
        "group_2": "1 of 5,576",
        "difference": "0.0 points",
        "interval": "-0.1 to 0.1",
        "trial_title": "Fetal ST Segment and T Wave Analysis in Labor"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=44",
  "request_id": "jJ7ak14BHPqgfIZA"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?